Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TRIM24
REST API REST API
Homo sapiens
TRIM24 is differentially expressed in 289 experiments: 120 organism parts: liver, ovary, ... (118 more);, 184 disease states: normal, prostate carcinoma, ... (182 more);, 87 cell types 430 cell lines 41 compound treatments and 74 other conditions.
Synonyms TIF1, Tif1a, RNF82, hTIF1
Orthologs Trim24 (Mus musculus)   TRIM24 (Gallus gallus)   Trim24 (Rattus norvegicus)   ENSCING00000014683 (Ciona intestinalis)   TRIM24 (Bos taurus)   Q1RPW5_CIOIN (Ciona intestinalis)   bon (Drosophila melanogaster)   trim24 (Xenopus laevis)   ENSCAFG00000004336 (Canis familiaris)   ENSCAFG00000024739 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligase activity, nuclear euchromatin, ligand-dependent nuclear receptor binding, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, protein catabolic process, intracellular, negative regulation of cell proliferation, protein ubiquitination, positive regulation of gene expression, metal ion binding, regulation of protein stability, receptor binding, transcription from RNA polymerase II promoter, sequence-specific DNA binding, transcription coactivator activity, nucleus, ubiquitin-protein ligase activity, chromatin binding, positive regulation of transcription, DNA-dependent, protein kinase activity, calcium ion homeostasis, zinc ion binding, regulation of apoptosis, histone acetyl-lysine binding, estrogen response element binding, regulation of vitamin D receptor signaling pathway, cellular response to estrogen stimulus, p53 binding, perichromatin fibrils, protein autophosphorylation, protein phosphorylation
InterPro Term Znf_B-box_chordata, Bbox_C, Znf_PHD-finger, Znf_RING, Znf_PHD, Znf_B-box, Bromodomain
UniProt Accession O15164, B4DYZ9, C9JPT4, E7ES63, F8WCX0
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY
Search EB-eye ENSG00000122779
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
K562
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT474
1
2
E-MTAB-37, E-MEXP-440, E-MTAB-62
424 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
2
2
E-TABM-130, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
stromal cell
1
2
E-MEXP-2034, E-MEXP-1327, E-GEOD-10797
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-MTAB-62, E-MTAB-680, ... (64 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-8121, E-GEOD-21912, E-GEOD-20602
mesothelioma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
neuroblastoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-2514
colon carcinoma
1
2
E-MTAB-57, E-GEOD-3726, E-MTAB-37
178 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-1417, E-GEOD-3720, E-TABM-868, ... (27 experiments)

Factor Value U/D Experiments
none
3
6
E-MEXP-1958, E-GEOD-412, E-TABM-868, E-GEOD-2803, E-GEOD-7307, ... (9 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
sapphyrin PCI-2050
1
E-GEOD-6400
tBHP
1
E-MEXP-2345
Cxcl12
1
1
E-GEOD-7307
35 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
56
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-3494, E-GEOD-18736, E-TABM-868, E-GEOD-18005, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-MEXP-1103, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM